LOS ANGELES, July 6, 2015 /PRNewswire/ -- ImmunoCellular
Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today
announced the establishment of an agreement with Novella Clinical
(Novella), to conduct the phase 3 registration trial of ICT-107 in
patients with newly diagnosed glioblastoma. Novella is a
full-service, global clinical research organization (CRO) providing
clinical trial services to small to mid-sized oncology companies.
The ICT-107 phase 3 trial will include approximately 120 clinical
sites in the US, Europe and
Canada, and will recruit about 400
patients with newly diagnosed glioblastoma. ImmunoCellular
anticipates initiating the phase 3 trial in the fourth quarter of
2015.
"Establishing this agreement with Novella Clinical moves us one
more critical step forward in the implementation of our phase 3
ICT-107 registrational trial," said Andrew
Gengos, ImmunoCellular Chief Executive Officer. "Novella's
special expertise in oncology clinical trials, combined with their
strong international network, experience working with oncology
cooperative groups, and reputation for high quality, efficiency and
cost-effectiveness, make them an excellent partner for our ICT-107
program. We are rapidly building the infrastructure for our phase 3
program and remain on track to initiate the trial later this
year."
Novella's President Richard Staub
added, "We are proud and very pleased to be selected to support
this proprietary oncology immunotherapy platform for glioblastoma.
We look forward to working alongside ImmunoCellular to navigate the
development and successful execution of this pivotal program to
ultimately benefit patients."
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that
is developing immune-based therapies for the treatment of brain and
other cancers. ImmunoCellular has concluded a phase 2 trial of its
lead product candidate, ICT-107, a dendritic cell-based cancer
immunotherapy targeting multiple tumor-associated antigens for
glioblastoma. ImmunoCellular's pipeline also includes: ICT-121, a
dendritic cell immunotherapy targeting CD133; ICT-140, a dendritic
cell immunotherapy targeting ovarian cancer antigens and cancer
stem cells; and the Stem-to-T-cell research program which engineers
the patient's hematopoietic stem cells to generate antigen-specific
cancer killing T-cells.
Forward-Looking Statements for ImmunoCellular Therapeutics
This press release contains certain forward-looking statements,
including statements regarding the timing for the initiation of a
registrational trial for ICT-107, development, manufacturing and
commercialization of ICT-107 in the EU, including the initiation of
a phase 3 study and potential for regulatory approval of ICT-107 by
the EMA. These statements are based on ImmunoCellular's current
expectations and involve significant risks and uncertainties,
including those described under the heading "Risk Factors" in
ImmunoCellular's most recently filed annual report on Form 10-K.
Except as required by law, ImmunoCellular undertakes no obligation
to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Logo -
http://photos.prnewswire.com/prnh/20140109/AQ43875LOGO
Contact:
ImmunoCellular Therapeutics, Ltd.
Investor Relations
Jane Green
415.348.0010 direct
415.652.4819 mobile
jane@jmgcomm.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/immunocellular-therapeutics-establishes-agreement-with-novella-clinical-to-conduct-ict-107-phase-3-registration-trial-in-glioblastoma-300108734.html
SOURCE ImmunoCellular Therapeutics, Ltd.